SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma

IndroductionColorectal cancer (CRC) is a prevalent malignancy and is the second leading cause of cancer-related mortality worldwide. 5-Fluorouracil (5-FU) is widely used in clinical intervention, however, drug resistance to 5-FU poses a significant challenge to treatment efficacy. Small nucleolar RN...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanzhi Wang, Huihui An, Yaou Zhang, Qing Rex Lyu, Zhe Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1564682/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850157725465444352
author Yanzhi Wang
Huihui An
Yaou Zhang
Yaou Zhang
Qing Rex Lyu
Zhe Zhang
author_facet Yanzhi Wang
Huihui An
Yaou Zhang
Yaou Zhang
Qing Rex Lyu
Zhe Zhang
author_sort Yanzhi Wang
collection DOAJ
description IndroductionColorectal cancer (CRC) is a prevalent malignancy and is the second leading cause of cancer-related mortality worldwide. 5-Fluorouracil (5-FU) is widely used in clinical intervention, however, drug resistance to 5-FU poses a significant challenge to treatment efficacy. Small nucleolar RNAs (snoRNAs) are a class of nuclear non-coding RNAs that mainly play roles in post-transcriptional RNA processing and modification in ribosomal RNA, which is crucial for sustaining protein synthesis. This study aimed to identify differentially expressed snoRNAs in CRC and pinpoint a specific snoRNA that may exert a synergistic effect with 5-FU administration.MethodsCombinatorial small RNA array of clinical samples and data analysis from The Cancer Genome Atlas (TCGA) database were used to identify the differentially expressed snoRNAs in colorectal cancer (CRC). To investigate the role of SNORA13 in CRC, loss-of-function (LoF) study was conducted using transient antisense oligonucleotides (ASOs) transfection and SNORA13 knockout with CRISPR-Cas9 genome editing in HT29 colon adenocarcinoma cell line. A combined administration of SNORA13-ASO and 5-Fluorouracil (5-FU) was performed in nude mice xenograft model to verify the synergistic inhibitory effect. RNA-seq, Ribo-seq and proteomics were performed to identify the downstream target of SNORA13, and qRT-PCR and Western Blot were used to confirm the results of multi-omics analysis.ResultsThe analysis of small RNA array data combined with the snoRNA expression profile in TCGA database determined that SNORA13 is commonly increased in CRC tissues. The LoF study revealed that the cell proliferation and colony formation are significantly suppressed upon SNORA13 deficiency. Next, the xenografted tumor model in nude mice demonstrated that the smaller tumorigenesis in SNORA13 knockout HT29 cell lines, and SNORA13 ASO enhances the anti-cancer efficacy of 5-FU. Finally, multi-omics analysis and molecular experimental validation revealed that nicotinamide N-methyltransferase (NNMT) is significantly suppressed in SNORA13 knockout HT29 cell lines.ConclusionOur study revealed SNORA13 is highly expressed in CRC and demonstrated knockdown of SNORA13, especially combined with 5-FU administration, may represent a promising therapeutic approach for CRC treatment.
format Article
id doaj-art-361adee1a14b4075b4e47cde68fda5c0
institution OA Journals
issn 1663-9812
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-361adee1a14b4075b4e47cde68fda5c02025-08-20T02:24:04ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-06-011610.3389/fphar.2025.15646821564682SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinomaYanzhi Wang0Huihui An1Yaou Zhang2Yaou Zhang3Qing Rex Lyu4Zhe Zhang5Medical Research Center, Chongqing General Hospital, Chongqing University, Chongqing, ChinaMedical Research Center, Chongqing General Hospital, Chongqing University, Chongqing, ChinaChina State Key Laboratory of Chemical Oncogenomics, Tsinghua Shenzhen International Graduate School, Shenzhen, ChinaKey Lab in Healthy Science and Technology of Shenzhen, Tsinghua Shenzhen International Graduate School, Shenzhen, ChinaMedical Research Center, Chongqing General Hospital, Chongqing University, Chongqing, ChinaDepartment of Chinese Medical Gastroenterology, China-Japan Friendship Hospital, Beijing, ChinaIndroductionColorectal cancer (CRC) is a prevalent malignancy and is the second leading cause of cancer-related mortality worldwide. 5-Fluorouracil (5-FU) is widely used in clinical intervention, however, drug resistance to 5-FU poses a significant challenge to treatment efficacy. Small nucleolar RNAs (snoRNAs) are a class of nuclear non-coding RNAs that mainly play roles in post-transcriptional RNA processing and modification in ribosomal RNA, which is crucial for sustaining protein synthesis. This study aimed to identify differentially expressed snoRNAs in CRC and pinpoint a specific snoRNA that may exert a synergistic effect with 5-FU administration.MethodsCombinatorial small RNA array of clinical samples and data analysis from The Cancer Genome Atlas (TCGA) database were used to identify the differentially expressed snoRNAs in colorectal cancer (CRC). To investigate the role of SNORA13 in CRC, loss-of-function (LoF) study was conducted using transient antisense oligonucleotides (ASOs) transfection and SNORA13 knockout with CRISPR-Cas9 genome editing in HT29 colon adenocarcinoma cell line. A combined administration of SNORA13-ASO and 5-Fluorouracil (5-FU) was performed in nude mice xenograft model to verify the synergistic inhibitory effect. RNA-seq, Ribo-seq and proteomics were performed to identify the downstream target of SNORA13, and qRT-PCR and Western Blot were used to confirm the results of multi-omics analysis.ResultsThe analysis of small RNA array data combined with the snoRNA expression profile in TCGA database determined that SNORA13 is commonly increased in CRC tissues. The LoF study revealed that the cell proliferation and colony formation are significantly suppressed upon SNORA13 deficiency. Next, the xenografted tumor model in nude mice demonstrated that the smaller tumorigenesis in SNORA13 knockout HT29 cell lines, and SNORA13 ASO enhances the anti-cancer efficacy of 5-FU. Finally, multi-omics analysis and molecular experimental validation revealed that nicotinamide N-methyltransferase (NNMT) is significantly suppressed in SNORA13 knockout HT29 cell lines.ConclusionOur study revealed SNORA13 is highly expressed in CRC and demonstrated knockdown of SNORA13, especially combined with 5-FU administration, may represent a promising therapeutic approach for CRC treatment.https://www.frontiersin.org/articles/10.3389/fphar.2025.1564682/fullSNORA135-fluorouracilcolorectal cancertranslation efficiencynicotinamide N-methyltransferase
spellingShingle Yanzhi Wang
Huihui An
Yaou Zhang
Yaou Zhang
Qing Rex Lyu
Zhe Zhang
SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma
Frontiers in Pharmacology
SNORA13
5-fluorouracil
colorectal cancer
translation efficiency
nicotinamide N-methyltransferase
title SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma
title_full SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma
title_fullStr SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma
title_full_unstemmed SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma
title_short SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma
title_sort snora13 antisense oligonucleotides enhances the therapeutical effects of 5 fluorouracil in colon adenocarcinoma
topic SNORA13
5-fluorouracil
colorectal cancer
translation efficiency
nicotinamide N-methyltransferase
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1564682/full
work_keys_str_mv AT yanzhiwang snora13antisenseoligonucleotidesenhancesthetherapeuticaleffectsof5fluorouracilincolonadenocarcinoma
AT huihuian snora13antisenseoligonucleotidesenhancesthetherapeuticaleffectsof5fluorouracilincolonadenocarcinoma
AT yaouzhang snora13antisenseoligonucleotidesenhancesthetherapeuticaleffectsof5fluorouracilincolonadenocarcinoma
AT yaouzhang snora13antisenseoligonucleotidesenhancesthetherapeuticaleffectsof5fluorouracilincolonadenocarcinoma
AT qingrexlyu snora13antisenseoligonucleotidesenhancesthetherapeuticaleffectsof5fluorouracilincolonadenocarcinoma
AT zhezhang snora13antisenseoligonucleotidesenhancesthetherapeuticaleffectsof5fluorouracilincolonadenocarcinoma